Back to News

Biological E and GVK BIO Announce Strategic R&D Partnership

July 31, 2019

Hyderabad, India — July 31, 2019 — GVK BIO, a leading global Contract Research and Development Organisation (CRDO), and BE Pharmaceuticals Inc (BE Inc), a rapidly growing pharmaceutical company that develops, manufactures and markets complex and critical injectable products, announced a strategic collaboration in drug product development.

As part of the partnership, GVK BIO will develop certain set of injectable products for BE Inc. Development work will include Pre-Formulation studies, Formulation Development, Analytical Method Development and Technology Transfer to a BE facility. The goal of the collaboration will be the successful regulatory submissions and marketing authorizations for the products in the US, Europe and RoW markets.

“GVK BIO’s Formulations Development team has the technical expertise and track record to deliver on projects, and we look forward to working with the BE team to accelerate product development timelines and reduce cost to market” said Manni Kantipudi, Director & Chief Executive Officer, GVK BIO.

“We are excited to work with GVK BIO, an established CRDO” said Narender Mantena, CEO, Speciality Generic Injectable, BE Pharmaceuticals. “This collaboration will support BE in building a robust pipeline, especially for critical injectable products”

GVK BIO, a Contract Research & Development Organization that services the global Pharmaceutical industry is headquartered in Hyderabad, India and has five sites across the globe. Established in 2001, GVK BIO serves large and small pharma clients across the R&D value chain with a focus on speed and quality, ensuring safety and compliance. GVK BIO’s team of over 2200 scientists, are supported by a no-conflict business model, modern facilities, strong customer-centric culture, and focus on bringing their customers’ products to market rapidly and cost effectively.

About Biological E. Limited
Biological E. Limited (BE) is a privately held company established in 1953. BE is a globally focused biopharmaceutical company, which develops, manufactures and markets innovative vaccines and biologics that respond to healthcare needs worldwide. The company’s product development efforts are driven by an internationally experienced management team and the company has several strategic partnerships with leading biotechnology and pharmaceutical companies and research institutes around the world.
BE Pharmaceuticals Inc is a subsidiary of Biological E. Limited and focuses on Speciality Generic Injectables.